Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France
Transplant International · 2023
DOI: 10.3389/ti.2023.11328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2023. Verfasst von Dominique Bertrand und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The first COVID-19 stay-at-home order came into effect in France on 17 March 2020. Immunocompromised patients were asked to isolate themselves, and outpatient clinic visits were dramatically reduced. In order to avoid visits to the hospital by belatacept-treated kidney transplant recipients (KTRs) during the initial period of the pandemic, we promptly converted 176 KTRs at two French transplant centers from once-monthly 5 mg/kg in-hospital belatacept infusion to once-weekly 125 mg subcutaneous abatacept injection. At the end of follow-up (3 months), 171 (97.16%) KTRs survived with a functioning graft, 2 (1.14%) had died, and 3 (1.70%) had experienced graft loss. Two patients (1.1%) experienced acute T cell–mediated rejection. Nineteen patients (10.80%) discontinued abatacept; 47% of the KTRs found the use of abatacept less restrictive than belatacept, and 38% would have preferred to continue abatacept. Mean eGFR remained stable compared to baseline. Seven patients (3.9%) had COVID-19; among these, two developed severe symptoms but survived. Only one patient had a de novo DSA. Side effects of abatacept injection were uncommon and non-severe. Our study reports for the first time in a large cohort that once-weekly injection of abatacept appears to be feasible and safe in KTRs previously treated with belatacept.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France.
- Department of Kidney Transplantation, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
- INSERM U1096, University of Rouen Normandy, Rouen, France.
Zitieren
APA
Bertrand, D., Brunel, M., Lebourg, L., Scemla, A., Lemoine, M., Amrouche, L., Laurent, C., Legendre, C., Guerrot, D., Anglicheau, D., & Sberro-Soussan, R. (2023). Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France. Transplant International. https://doi.org/10.3389/ti.2023.11328
Vancouver
Bertrand D, Brunel M, Lebourg L, Scemla A, Lemoine M, Amrouche L, et al. Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France. Transplant International. 2023. doi:10.3389/ti.2023.11328
BibTeX
@article{Bertrand2023,
author = {Bertrand, Dominique and Brunel, Mélanie and Lebourg, Ludivine and Scemla, Anne and Lemoine, Mathilde and Amrouche, Lucile and Laurent, Charlotte and Legendre, Christophe and Guerrot, Dominique and Anglicheau, Dany and Sberro-Soussan, Rebecca},
title = {Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France},
journal = {Transplant International},
year = {2023},
doi = {10.3389/ti.2023.11328}
}
EUVIMED